Sutimlimab Cad denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sutimlimab cad are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Sutimlimab for Cold Agglutinin Disease — "Not FDA-Approved"

A "not FDA-approved" denial applied to sutimlimab for cold agglutinin disease (CAD) is one of the most straightforward denials to challenge, because sutimlimab has received FDA approval specifically for the treatment of hemolytic anemia in adults with CAD. If the drug is being prescribed for its FDA-approved indication, the denial's stated basis is factually incorrect and should be corrected at the first level of appeal with minimal documentation. However, it is important to confirm that the prescribed use is on-label before proceeding — an off-label use would require a different appeal strategy.

## Why This Denial Is Appealable

FDA approval is the regulatory standard for established therapy in the United States. If sutimlimab is prescribed for its approved CAD indication, the denial directly contradicts FDA's determination. Most BCBS medical policies and standard-of-care definitions treat FDA-approved uses as presumptively not experimental or investigational. Presenting the FDA approval documentation alongside the prescribing label should be sufficient to trigger reconsideration. If BCBS maintains the denial after reviewing this evidence, the denial may reflect a formulary or prior authorization issue that was mislabeled, which should be clarified in writing.

## Federal Appeal Framework

• Internal appeal (Level 1): File promptly. The letter should be brief and targeted: state that the drug has FDA approval for the exact indication prescribed, attach the FDA label, and request immediate reconsideration.
• External review (ACA §2719): If the internal appeal is denied, request independent external review within approximately four months of the final denial. An IRO will assess the factual basis of the FDA-status determination.
• ERISA §503: Self-funded plan members may request the administrative record to understand why an approved drug was coded as unapproved.
• Expedited review: Available for urgent clinical situations.

## Documentation to Gather

• FDA prescribing information (package insert) for sutimlimab, including the approved indication
• Prescribing clinician's letter confirming the use is on-label
• Confirmed CAD diagnosis documentation
• BCBS's denial letter identifying the specific basis for the not-FDA-approved determination
• BCBS's published experimental/investigational or coverage policy for sutimlimab

## Criteria-Mapping Structure

The appeal letter structure for this denial type is simple: (1) state the FDA approval date and approved indication; (2) confirm the prescribed use matches the approved indication; (3) request that BCBS identify — in writing — what specific regulatory or clinical basis supports classifying an FDA-approved, on-label drug as not approved. If BCBS responds by shifting to a different denial rationale (e.g., non-formulary or prior authorization), you have successfully corrected the original denial and can address the new rationale in a follow-up appeal.